Rare Biomarker Specimen Collection and Stabilization Market Report: Trends, Forecast and Competitive Analysis
Get it in 2 to 4 weeks by ordering today
The future of the global rare biomarker specimen collection and stabilization market looks promising with opportunities in the NIPT (Non Invasive Prenatal Testing), oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, and cardiovascular diseases. The global rare biomarker specimen collection and stabilization market is expected to grow with a CAGR of 10%-12% from 2020 to 2025. The major drivers for this market are increasing research activities for depicting the role of circulating biomarkers in disease management, and rising demand for non-invasive cancer diagnostic and personalized medicines.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global rare biomarker specimen collection and stabilization market report, please download the report brochure.
The study includes trends and forecast for the global rare biomarker specimen collection and stabilization market by product, type, specimen, nucleic acid and other biomolecules, application, end use, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
Within this market, research will remain the largest segment by end use over the forecast period due to increasing interest in rare biomarkers owing to their exclusive functions as intercellular messengers, their therapeutic potential in disease diagnostics, abilities to alter recipient cell bioactivities, and growing applications in drug delivery.
North America will remain the largest region over the forecast period due to the presence of a large number of clients and substantial number of FDA approved products such as isolation kits for both clinical use and research use due to rising liquid biopsy and assisted reproductive technology space in the region.
Features of the Global Rare Biomarker Specimen Collection and Stabilization Market
Q.1 What are some of the most promising potential, high-growth opportunities for the global rare biomarker specimen collection and stabilization market by product (isolation kits & reagents, blood collection tubes, and systems), type (circulating call free DNA (ccfDNA), circulating tumor cells (CTCs), and exosomes/extracellular vesicles), specimen (serum/plasma and others), nucleic acid & other biomolecules (RNA, DNA, and others), application (NIPT, oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases, and others), end use (research (research labs/CROs and academic institutes) and diagnostics (laboratories, hospitals and prenatal clinic)), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global rare biomarker specimen collection and stabilization market?
Q.5 What are the business risks and threats to the global rare biomarker specimen collection and stabilization market?
Q.6 What are the emerging trends in this rare biomarker specimen collection and stabilization market and the reasons behind them?
Q.7 What are some changing demands of customers in this rare biomarker specimen collection and stabilization market?
Q.8 What are the new developments in this rare biomarker specimen collection and stabilization market? Which companies are leading these developments?
Q.9 Who are the major players in this rare biomarker specimen collection and stabilization market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this rare biomarker specimen collection and stabilization market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global rare biomarker specimen collection and stabilization market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Product (Isolation Kits & Reagents, Blood Collection Tubes, and Systems), Type (ccfDNA, CTCs, and Exosomes/Extracellular Vesicles), Specimen (Serum/Plasma and Others), Nucleic Acid & Other Biomolecules (RNA, DNA, and Others), Application (NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others), and End Use (Research (Research Labs/CROs and Academic Institutes) and Diagnostics (Laboratories, Hospitals and Prenatal Clinic))
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
The future of the global rare biomarker specimen collection and stabilization market looks promising with opportunities in the NIPT (Non Invasive Prenatal Testing), oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, and cardiovascular diseases. The global rare biomarker specimen collection and stabilization market is expected to grow with a CAGR of 10%-12% from 2020 to 2025. The major drivers for this market are increasing research activities for depicting the role of circulating biomarkers in disease management, and rising demand for non-invasive cancer diagnostic and personalized medicines.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global rare biomarker specimen collection and stabilization market report, please download the report brochure.
The study includes trends and forecast for the global rare biomarker specimen collection and stabilization market by product, type, specimen, nucleic acid and other biomolecules, application, end use, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
- Isolation Kits & Reagents
- Blood Collection Tubes
- Systems
- Circulating Call Free DNA (ccfDNA)
- Circulating Tumor Cells (CTCs)
- Exosomes/Extracellular Vesicles
- Serum/Plasma
- Others
- RNA (Ribonucleic Acid)
- DNA (Deoxyribonucleic Acid)
- Others
- NIPT
- Oncology
- Transcriptomics
- Pharmacogenomics
- Transplant Rejection
- Population Screening
- Cardiovascular Diseases
- Others
- Research
- Research Labs/CROs
- Academic Institutes
- Diagnostics
- Laboratories
- Hospitals
- Prenatal Clinic
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- The Rest of the World
- Brazil
Within this market, research will remain the largest segment by end use over the forecast period due to increasing interest in rare biomarkers owing to their exclusive functions as intercellular messengers, their therapeutic potential in disease diagnostics, abilities to alter recipient cell bioactivities, and growing applications in drug delivery.
North America will remain the largest region over the forecast period due to the presence of a large number of clients and substantial number of FDA approved products such as isolation kits for both clinical use and research use due to rising liquid biopsy and assisted reproductive technology space in the region.
Features of the Global Rare Biomarker Specimen Collection and Stabilization Market
- Market Size Estimates: Global rare biomarker specimen collection and stabilization market size estimation in terms of value ($M) shipment.
- Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.
- Segmentation Analysis: Global rare biomarker specimen collection and stabilization market size by various segments, such as product, type, specimen, nucleic acid & other biomolecules, application, and end use in terms of value.
- Regional Analysis: Global rare biomarker specimen collection and stabilization market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different product, type, specimen, nucleic acid & other biomolecules, application, end use, and region for the global rare biomarkers specimen collection and stabilization market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global rare biomarker specimen collection and stabilization market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
Q.1 What are some of the most promising potential, high-growth opportunities for the global rare biomarker specimen collection and stabilization market by product (isolation kits & reagents, blood collection tubes, and systems), type (circulating call free DNA (ccfDNA), circulating tumor cells (CTCs), and exosomes/extracellular vesicles), specimen (serum/plasma and others), nucleic acid & other biomolecules (RNA, DNA, and others), application (NIPT, oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases, and others), end use (research (research labs/CROs and academic institutes) and diagnostics (laboratories, hospitals and prenatal clinic)), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global rare biomarker specimen collection and stabilization market?
Q.5 What are the business risks and threats to the global rare biomarker specimen collection and stabilization market?
Q.6 What are the emerging trends in this rare biomarker specimen collection and stabilization market and the reasons behind them?
Q.7 What are some changing demands of customers in this rare biomarker specimen collection and stabilization market?
Q.8 What are the new developments in this rare biomarker specimen collection and stabilization market? Which companies are leading these developments?
Q.9 Who are the major players in this rare biomarker specimen collection and stabilization market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this rare biomarker specimen collection and stabilization market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global rare biomarker specimen collection and stabilization market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Product (Isolation Kits & Reagents, Blood Collection Tubes, and Systems), Type (ccfDNA, CTCs, and Exosomes/Extracellular Vesicles), Specimen (Serum/Plasma and Others), Nucleic Acid & Other Biomolecules (RNA, DNA, and Others), Application (NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others), and End Use (Research (Research Labs/CROs and Academic Institutes) and Diagnostics (Laboratories, Hospitals and Prenatal Clinic))
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Rare Biomarker Specimen Collection and Stabilization Market Trends and Forecast
3.3: Global Rare Biomarker Specimen Collection and Stabilization Market by Product
3.3.1: Isolation Kits & Reagents
3.3.2: Blood Collection Tubes
3.3.3: Systems
3.4: Global Rare Biomarker Specimen Collection and Stabilization Market by Type
3.4.1: Circulating Call Free DNA (ccfDNA)
3.4.2: Circulating Tumor Cells (CTCs)
3.4.3: Exosomes/Extracellular Vesicles
3.5: Global Rare Biomarker Specimen Collection and Stabilization Market by Specimen
3.5.1: Serum/Plasma
3.5.2: Others
3.6: Global Rare Biomarker Specimen Collection and Stabilization Market by Nucleic Acid & Other Biomolecules
3.6.1: RNA
3.6.2: DNA
3.6.3: Others
3.7: Global Rare Biomarker Specimen Collection and Stabilization Market by Application
3.7.1: NIPT
3.7.2: Oncology
3.7.3: Transcriptomics
3.7.4: Pharmacogenomics
3.7.5: Transplant Rejection
3.7.6: Population Screening
3.7.7: Cardiovascular Diseases
3.7.8: Others
3.8: Global Rare Biomarker Specimen Collection and Stabilization Market by End Use
3.8.1: Research
3.8.1.1: Research Labs/CROs
3.8.1.2: Academic Institutes
3.8.2: Diagnostics
3.8.2.1: Laboratories
3.8.2.2: Hospitals
3.8.2.3: Prenatal Clinic
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Rare Biomarker Specimen Collection and Stabilization Market by Region
4.2: North American Rare Biomarkers Specimen Collection And Stabilization Market
4.2.1: Market by Product: Isolation Kits & Reagents, Blood Collection Tubes, and Systems
4.2.2: Market by Type: Circulating Call Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles
4.2.3: Market by Specimen: Serum/Plasma and Others
4.2.4: Market by Nucleic Acid & Other Biomolecules: RNA, DNA, and Others
4.2.5: Market by Application: NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others
4.2.6: Market by End Use: Research (Research Labs/CROs and Academic Institutes), Diagnostics (Laboratories, Hospitals, and Prenatal Clinic)
4.2.7: The United States Rare Biomarkers Specimen Collection And Stabilization Market
4.2.8: The Canadian Rare Biomarkers Specimen Collection And Stabilization Market
4.2.9: The Mexican Rare Biomarkers Specimen Collection And Stabilization Market
4.3: European Rare Biomarkers Specimen Collection And Stabilization Market
4.3.1: Market by Product: Isolation Kits & Reagents, Blood Collection Tubes, and Systems
4.3.2: Market by Type: Circulating Call Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles
4.3.3: Market by Specimen: Serum/Plasma and Others
4.3.4: Market by Nucleic Acid & Other Biomolecules: RNA, DNA, and Others
4.3.5: Market by Application: NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others
4.3.6: Market by End Use: Research (Research Labs/CROs and Academic Institutes), Diagnostics (Laboratories, Hospitals, and Prenatal Clinic)
4.3.7: The Rare Biomarkers Specimen Collection And Stabilization Market of United Kingdom
4.3.8: The German Rare Biomarkers Specimen Collection And Stabilization Market
4.3.9: The French Rare Biomarkers Specimen Collection And Stabilization Market
4.4: APAC Rare Biomarkers Specimen Collection And Stabilization Market
4.4.1: Market by Product: Isolation Kits & Reagents, Blood Collection Tubes, and Systems
4.4.2: Market by Type: Circulating Call Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles
4.4.3: Market by Specimen: Serum/Plasma and Others
4.4.4: Market by Nucleic Acid & Other Biomolecules: RNA, DNA, and Others
4.4.5: Market by Application: NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others
4.4.6: Market by End Use: Research (Research Labs/CROs and Academic Institutes), Diagnostics (Laboratories, Hospitals, and Prenatal Clinic)
4.4.7: The Chinese Rare Biomarkers Specimen Collection And Stabilization Market
4.4.8: The Indian Rare Biomarkers Specimen Collection And Stabilization Market
4.4.9: The Japanese Rare Biomarkers Specimen Collection And Stabilization Market
4.5: ROW Rare Biomarkers Specimen Collection And Stabilization Market
4.5.1: Market by Product: Isolation Kits & Reagents, Blood Collection Tubes, and Systems
4.5.2: Market by Type: Circulating Call Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles
4.5.3: Market by Specimen: Serum/Plasma and Others
4.5.4: Market by Nucleic Acid & Other Biomolecules: RNA, DNA, and Others
4.5.5: Market by Application: NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others
4.5.6: Market by End Use: Research (Research Labs/CROs and Academic Institutes), Diagnostics (Laboratories, Hospitals, and Prenatal Clinic)
4.5.7: Brazilian Rare Biomarkers Specimen Collection And Stabilization Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Product
7.1.2: Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Type
7.1.3: Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Specimen
7.1.4: Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Nucleic Acid & Other Biomolecules
7.1.5: Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Application
7.1.6: Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by End Use
7.1.7: Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Region
7.2: Emerging Trends in the Global Rare Biomarker Specimen Collection and Stabilization Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Rare Biomarker Specimen Collection and Stabilization Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Rare Biomarker Specimen Collection and Stabilization Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Agena Bioscience
8.2: BioChain Institute, Inc.
8.3: Epic Sciences
8.4: Biovision Inc.
8.5: Gen Technology Inc.
8.6: Roche
8.7: ANGLE plc
8.8: AS ONE INTERNATIONAL
8.9: Biolidics Limited
8.10: Biomatrica
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Rare Biomarker Specimen Collection and Stabilization Market Trends and Forecast
3.3: Global Rare Biomarker Specimen Collection and Stabilization Market by Product
3.3.1: Isolation Kits & Reagents
3.3.2: Blood Collection Tubes
3.3.3: Systems
3.4: Global Rare Biomarker Specimen Collection and Stabilization Market by Type
3.4.1: Circulating Call Free DNA (ccfDNA)
3.4.2: Circulating Tumor Cells (CTCs)
3.4.3: Exosomes/Extracellular Vesicles
3.5: Global Rare Biomarker Specimen Collection and Stabilization Market by Specimen
3.5.1: Serum/Plasma
3.5.2: Others
3.6: Global Rare Biomarker Specimen Collection and Stabilization Market by Nucleic Acid & Other Biomolecules
3.6.1: RNA
3.6.2: DNA
3.6.3: Others
3.7: Global Rare Biomarker Specimen Collection and Stabilization Market by Application
3.7.1: NIPT
3.7.2: Oncology
3.7.3: Transcriptomics
3.7.4: Pharmacogenomics
3.7.5: Transplant Rejection
3.7.6: Population Screening
3.7.7: Cardiovascular Diseases
3.7.8: Others
3.8: Global Rare Biomarker Specimen Collection and Stabilization Market by End Use
3.8.1: Research
3.8.1.1: Research Labs/CROs
3.8.1.2: Academic Institutes
3.8.2: Diagnostics
3.8.2.1: Laboratories
3.8.2.2: Hospitals
3.8.2.3: Prenatal Clinic
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Rare Biomarker Specimen Collection and Stabilization Market by Region
4.2: North American Rare Biomarkers Specimen Collection And Stabilization Market
4.2.1: Market by Product: Isolation Kits & Reagents, Blood Collection Tubes, and Systems
4.2.2: Market by Type: Circulating Call Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles
4.2.3: Market by Specimen: Serum/Plasma and Others
4.2.4: Market by Nucleic Acid & Other Biomolecules: RNA, DNA, and Others
4.2.5: Market by Application: NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others
4.2.6: Market by End Use: Research (Research Labs/CROs and Academic Institutes), Diagnostics (Laboratories, Hospitals, and Prenatal Clinic)
4.2.7: The United States Rare Biomarkers Specimen Collection And Stabilization Market
4.2.8: The Canadian Rare Biomarkers Specimen Collection And Stabilization Market
4.2.9: The Mexican Rare Biomarkers Specimen Collection And Stabilization Market
4.3: European Rare Biomarkers Specimen Collection And Stabilization Market
4.3.1: Market by Product: Isolation Kits & Reagents, Blood Collection Tubes, and Systems
4.3.2: Market by Type: Circulating Call Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles
4.3.3: Market by Specimen: Serum/Plasma and Others
4.3.4: Market by Nucleic Acid & Other Biomolecules: RNA, DNA, and Others
4.3.5: Market by Application: NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others
4.3.6: Market by End Use: Research (Research Labs/CROs and Academic Institutes), Diagnostics (Laboratories, Hospitals, and Prenatal Clinic)
4.3.7: The Rare Biomarkers Specimen Collection And Stabilization Market of United Kingdom
4.3.8: The German Rare Biomarkers Specimen Collection And Stabilization Market
4.3.9: The French Rare Biomarkers Specimen Collection And Stabilization Market
4.4: APAC Rare Biomarkers Specimen Collection And Stabilization Market
4.4.1: Market by Product: Isolation Kits & Reagents, Blood Collection Tubes, and Systems
4.4.2: Market by Type: Circulating Call Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles
4.4.3: Market by Specimen: Serum/Plasma and Others
4.4.4: Market by Nucleic Acid & Other Biomolecules: RNA, DNA, and Others
4.4.5: Market by Application: NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others
4.4.6: Market by End Use: Research (Research Labs/CROs and Academic Institutes), Diagnostics (Laboratories, Hospitals, and Prenatal Clinic)
4.4.7: The Chinese Rare Biomarkers Specimen Collection And Stabilization Market
4.4.8: The Indian Rare Biomarkers Specimen Collection And Stabilization Market
4.4.9: The Japanese Rare Biomarkers Specimen Collection And Stabilization Market
4.5: ROW Rare Biomarkers Specimen Collection And Stabilization Market
4.5.1: Market by Product: Isolation Kits & Reagents, Blood Collection Tubes, and Systems
4.5.2: Market by Type: Circulating Call Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles
4.5.3: Market by Specimen: Serum/Plasma and Others
4.5.4: Market by Nucleic Acid & Other Biomolecules: RNA, DNA, and Others
4.5.5: Market by Application: NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others
4.5.6: Market by End Use: Research (Research Labs/CROs and Academic Institutes), Diagnostics (Laboratories, Hospitals, and Prenatal Clinic)
4.5.7: Brazilian Rare Biomarkers Specimen Collection And Stabilization Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Product
7.1.2: Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Type
7.1.3: Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Specimen
7.1.4: Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Nucleic Acid & Other Biomolecules
7.1.5: Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Application
7.1.6: Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by End Use
7.1.7: Growth Opportunities for the Global Rare Biomarker Specimen Collection and Stabilization Market by Region
7.2: Emerging Trends in the Global Rare Biomarker Specimen Collection and Stabilization Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Rare Biomarker Specimen Collection and Stabilization Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Rare Biomarker Specimen Collection and Stabilization Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Agena Bioscience
8.2: BioChain Institute, Inc.
8.3: Epic Sciences
8.4: Biovision Inc.
8.5: Gen Technology Inc.
8.6: Roche
8.7: ANGLE plc
8.8: AS ONE INTERNATIONAL
8.9: Biolidics Limited
8.10: Biomatrica
